In:
Drug Testing and Analysis, Wiley, Vol. 10, No. 8 ( 2018-08), p. 1328-1335
Abstract:
MAM‐2201 is a fluorinated naphthoylindole synthetic cannabinoid with potent psychoactive properties that has been detected as an active ingredient in herbal incense blends. To gain a greater understanding of MAM‐2201 metabolism and to compare its metabolic fate in humans with those in animals, the metabolism of MAM‐2201 in human, mouse, and rat hepatocytes was investigated using liquid chromatography–high‐resolution mass spectrometry combined with targeted and non‐targeted metabolite profiling approaches. Nineteen phase I metabolites (M1–M19) reported previously in human liver microsomes and 13 novel metabolites were identified in human, mouse, and rat hepatocytes: 1 phase I metabolite (M20) and 12 phase II metabolites including 6 glucuronides (G1–G6), 1 sulfate (S1), and 5 glutathione (GSH) conjugates (GS1–GS5) of MAM‐2201 metabolites. G3 was human‐specific, but M20, G1, G2, and 5 GSH conjugates were rat‐specific, indicating species‐related differences in MAM‐2201 metabolism. The findings in the present study can be useful for the experimental design and assessment of metabolism‐mediated toxic risk of MAM‐2201.
Type of Medium:
Online Resource
ISSN:
1942-7603
,
1942-7611
Language:
English
Publisher:
Wiley
Publication Date:
2018
detail.hit.zdb_id:
2462344-1
SSG:
15,3
SSG:
31
Bookmarklink
